We noted an error in the last paragraph of our last post. The reference to patent number ‘953 should have read ‘891. The paragraph should read:
"Taking the above into account, if the Indian patent application was to be held invalid for some of the claims, but not those covered by ‘891, Roche could still potentially block generic companies from making Valgancicovir if they adopt the same intermediates route. It will be interesting to see whether the Indian companies can work around this."